[go: up one dir, main page]

WO2002000241A3 - Compositions and methods for regulating the cell cycle using a ki gene or polypeptide - Google Patents

Compositions and methods for regulating the cell cycle using a ki gene or polypeptide Download PDF

Info

Publication number
WO2002000241A3
WO2002000241A3 PCT/EP2001/008096 EP0108096W WO0200241A3 WO 2002000241 A3 WO2002000241 A3 WO 2002000241A3 EP 0108096 W EP0108096 W EP 0108096W WO 0200241 A3 WO0200241 A3 WO 0200241A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cell cycle
polypeptide
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/008096
Other languages
French (fr)
Other versions
WO2002000241A2 (en
Inventor
Didier Branellec
Elisabeth Lavenne
Roux Aude Le
Abderrahim Mahfoudi
Harris Perlman
Kenneth Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to AU2001289652A priority Critical patent/AU2001289652A1/en
Publication of WO2002000241A2 publication Critical patent/WO2002000241A2/en
Publication of WO2002000241A3 publication Critical patent/WO2002000241A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates, generally, to compositions and methods for regulating the cell cycle, in particular apoptosis. The invention relates more specifically to compositions and methods using a Ki gene or polypeptide to regulate the cell cycle, in particular apoptosis, in cells, in vitro, ex vivo or in vivo. The invention also relates to compositions, vectors, cells and the like, which can be used to implement the above methods. This invention can be used to protect cells from apoptosis or to mediate or enhance apoptosis in cells, in various physio-pathological conditions.
PCT/EP2001/008096 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide Ceased WO2002000241A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289652A AU2001289652A1 (en) 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21479000P 2000-06-28 2000-06-28
US60/214,790 2000-06-28

Publications (2)

Publication Number Publication Date
WO2002000241A2 WO2002000241A2 (en) 2002-01-03
WO2002000241A3 true WO2002000241A3 (en) 2002-10-17

Family

ID=22800421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008096 Ceased WO2002000241A2 (en) 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide

Country Status (2)

Country Link
AU (1) AU2001289652A1 (en)
WO (1) WO2002000241A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560984B2 (en) 2009-10-29 2017-02-07 The Nielsen Company (Us), Llc Analysis of controlled and automatic attention for introduction of stimulus material

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016459A1 (en) * 1995-10-31 1997-05-09 Rhone-Poulenc Rorer S.A. Use of protein gax for treating cancer
WO1998017686A1 (en) * 1996-10-18 1998-04-30 Rhone-Poulenc Rorer S.A. Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016459A1 (en) * 1995-10-31 1997-05-09 Rhone-Poulenc Rorer S.A. Use of protein gax for treating cancer
WO1998017686A1 (en) * 1996-10-18 1998-04-30 Rhone-Poulenc Rorer S.A. Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, (1996) VOL. 94, NO. 8 SUPPL., PP. I472. MEETING INFO.: 69TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION NEW ORLEANS, LOUISIANA, USA NOVEMBER 10-13, 1996 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; MAHFOUDI, ABDERRAHIM (1) ET AL: "Identification of a repressor domain in the growth arrest homeobox gene (GAX) that interacts with the nuclear antigen Ki.", XP002034391, retrieved from STN *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560984B2 (en) 2009-10-29 2017-02-07 The Nielsen Company (Us), Llc Analysis of controlled and automatic attention for introduction of stimulus material

Also Published As

Publication number Publication date
AU2001289652A1 (en) 2002-01-08
WO2002000241A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2004044158A3 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
WO2005003320A3 (en) Neuronal differentiation of stem cells
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
AU2003216058A8 (en) Mammalian neural stem cells, compositions and uses thereof
NZ712789A (en) Placental stem cell populations
IL152106A0 (en) Embryonic stem cells, neural progenitor cells derived therefrom and methods for the preparation thereof
WO2000053724A3 (en) Compositions and methods for the modification of gene transcription
WO2002074969A3 (en) Matrix attachment regions and methods for use thereof
ZA200006594B (en) DSRNA-mediated regulation of gene expression in plants.
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
AU2002301347A1 (en) Embryonic stem cells and neural progenitor cells derived therefrom
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
MXPA02003232A (en) Compositions and methods for altering gene expression.
WO2001004282A3 (en) Replication-competent anti-cancer vectors
WO2002060914A3 (en) Identification of small rnas and orfs form e. coli as mediators of cell and intercell regulation
WO2004007664A3 (en) Nucleic acid vectors
WO2002034890A3 (en) Pluripotential stem cells
WO2004063341A3 (en) Hematopoietic stem cell niche cells
WO2004044127A3 (en) Stem cell populations
WO2002000241A3 (en) Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
AU8371501A (en) Manipulation of plant senescence using an MYB gene promoter and cytokinin biosyntyhesis genes
WO2002086112A3 (en) Nucleic acid molecules encoding starch degrading enzymes
WO2001018192A3 (en) Synthetic vectors, transgenic plants containing them, and methods for obtaining them
WO2000049137A3 (en) Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell
WO2004075315A3 (en) Battery containing fibrous material

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP